Literature DB >> 10840192

Improving drug solubility for oral delivery using solid dispersions.

C Leuner1, J Dressman.   

Abstract

The solubility behaviour of drugs remains one of the most challenging aspects in formulation development. With the advent of combinatorial chemistry and high throughput screening, the number of poorly water soluble compounds has dramatically increased. Although solid solutions have tremendous potential for improving drug solubility, 40 years of research have resulted in only a few marketed products using this approach. With the introduction of new manufacturing technologies such as hot melt extrusion, it should be possible to overcome problems in scale-up and for this reason solid solutions are enjoying a renaissance. This article begins with an overview of the historical background and definitions of the various systems including eutectic mixtures, solid dispersions and solid solutions. The remainder of the article is devoted to the production, the different carriers and the methods used for the characterization of solid dispersions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840192     DOI: 10.1016/s0939-6411(00)00076-x

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  269 in total

1.  Amphotericin B delivery from bone cement increases with porosity but strength decreases.

Authors:  Chris Kweon; Alex C McLaren; Christine Leon; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

2.  Dissolution and solid-state characterization of poorly water-soluble drugs in the presence of a hydrophilic carrier.

Authors:  Rahmat Talukder; Chase Reed; Thomas Dürig; Muhammad Hussain
Journal:  AAPS PharmSciTech       Date:  2011-09-20       Impact factor: 3.246

3.  Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning.

Authors:  Geert Verreck; Iksoo Chun; Jef Peeters; Joel Rosenblatt; Marcus E Brewster
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

4.  Release profile and characteristics of electrosprayed particles for oral delivery of a practically insoluble drug.

Authors:  Adam Bohr; Jakob Kristensen; Mark Dyas; Mohan Edirisinghe; Eleanor Stride
Journal:  J R Soc Interface       Date:  2012-04-25       Impact factor: 4.118

5.  A practical method to predict physical stability of amorphous solid dispersions.

Authors:  Stéphanie Greco; Jean-René Authelin; Caroline Leveder; Audrey Segalini
Journal:  Pharm Res       Date:  2012-03-16       Impact factor: 4.200

6.  In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate.

Authors:  Evren Gundogdu; V Mangas-Sanjuan; Isabel Gonzalez-Alvarez; Marival Bermejo; Ercument Karasulu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-11       Impact factor: 2.441

Review 7.  Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A Review.

Authors:  Justin S LaFountaine; James W McGinity; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2015-08-26       Impact factor: 3.246

8.  Nonaqueous gel for the transdermal delivery of a DTPA penta-ethyl ester prodrug.

Authors:  Yong Zhang; Matthew P Sadgrove; Katsuhiko Sueda; Yu-Tsai Yang; Erik K Pacyniak; John R Kagel; Brenda A Braun; William C Zamboni; Russell J Mumper; Michael Jay
Journal:  AAPS J       Date:  2013-02-07       Impact factor: 4.009

9.  Solid dispersions of the penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA): formulation design and optimization studies.

Authors:  Yu-Tsai Yang; Anthony J Di Pasqua; Yong Zhang; Katsuhiko Sueda; Michael Jay
Journal:  Pharm Dev Technol       Date:  2013-09-19       Impact factor: 3.133

10.  Spatial characterization of hot melt extruded dispersion systems using thermal atomic force microscopy methods: the effects of processing parameters on phase separation.

Authors:  Jonathan G Moffat; Sheng Qi; Duncan Q M Craig
Journal:  Pharm Res       Date:  2014-02-20       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.